Timegadine is a competitive inhibitor of COX and lipo-oxygenase, with IC50s ranging from 5 nM (washed rabbit platelets) to 20 μM (rat brain) for COX and 100 μM for lipo-oxygenase both in the cytosol fraction of horse platelet homogenates and in washed rabbit platelets.

Timegadine is a potent, competitive COX and lipo-oxygenase inhibitor, with IC50s ranging from 5 nM (washed rabbit platelets) to 20 μM (rat brain) for COX and 100 μM for lipo-oxygenase both in the cytosol fraction of horse platelet homogenates, and in washed rabbit platelets[2],and is a new antiinflammatory agent,

Timegadine, a new anti-inflammatory agent, is a potent, competitive inhibitor of prostaglandin synthetase, additionally inhibiting cyclo-oxygenase (COX) and lipoxygenase. Administering Timegadine orally at doses ranging from 10 to 30 mg/kg daily effectively suppresses both the initial and subsequent lesions of adjuvant arthritis, particularly when treatment commences on the induction day and extends for 28 days. Notably, Timegadine can prevent the swelling of the non-injected paw for up to 28 days post-adjuvant injection, especially when administered five days before and after disease onset, mirroring the impact of cyclophosphamide[1].